Holen Sie sich die Stockscreener-App
100.83
3.94%
-4.14
Handel nachbörslich:
100.83
Schlusskurs vom Vortag:
$104.97
Offen:
$105.27
24-Stunden-Volumen:
854.91K
Relative Volume:
1.35
Marktkapitalisierung:
$4.96B
Einnahmen:
$338.46M
Nettoeinkommen (Verlust:
$-310.96M
KGV:
-15.44
EPS:
-6.53
Netto-Cashflow:
$-132.82M
1W Leistung:
-9.73%
1M Leistung:
-2.77%
6M Leistung:
-2.21%
1J Leistung:
+17.27%
1-Tages-Spanne:
$100.78
$105.86
1-Wochen-Bereich:
$100.78
$113.98
52-Wochen-Spanne:
$72.21
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Firmenname
Axsome Therapeutics Inc
Sektor
Branche
Telefon
(212) 332-3241
Adresse
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Vergleichen Sie AXSM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
100.83 | 5.17B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-07 | Eingeleitet | Jefferies | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-31 | Bestätigt | Mizuho | Outperform |
| 2024-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-06 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-04-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2024-01-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-08-08 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Eingeleitet | Piper Sandler | Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2022-09-07 | Fortgesetzt | Mizuho | Buy |
| 2021-08-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Eingeleitet | Berenberg | Buy |
| 2021-01-08 | Eingeleitet | Jefferies | Buy |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-09-29 | Eingeleitet | BofA Securities | Underperform |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-14 | Eingeleitet | Cowen | Outperform |
| 2019-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-16 | Bestätigt | Guggenheim | Buy |
| 2019-10-16 | Eingeleitet | Guggenheim | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-28 | Eingeleitet | SunTrust | Buy |
| 2019-05-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-08 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-15 | Bestätigt | H.C. Wainwright | Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2015-12-15 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
How strong is Axsome Therapeutics Inc. company’s balance sheetFree Market Dynamics Reports - jammulinksnews.com
What makes Axsome Therapeutics Inc. stock price move sharplyHigh-yield portfolio picks - jammulinksnews.com
Published on: 2025-07-27 23:41:07 - jammulinksnews.com
Is Axsome Therapeutics Inc. stock overvalued or undervaluedDynamic profit expansion - jammulinksnews.com
When is Axsome Therapeutics Inc. stock expected to show significant growth - jammulinksnews.com
What catalysts could drive Axsome Therapeutics Inc. stock higher in 2025Unprecedented profit potential - jammulinksnews.com
How does Axsome Therapeutics Inc. generate profit in a changing economyUnprecedented profit potential - jammulinksnews.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Knights of Columbus Asset Advisors LLC - MarketBeat
Q3 EPS Estimate for Axsome Therapeutics Raised by Analyst - MarketBeat
Axsome Therapeutics: Navigating Setbacks with a Strong Pipeline and Analyst Confidence - AInvest
Axsome: Some Recent Setbacks, Some Recent Wins — Still A Buy (NASDAQ:AXSM) - Seeking Alpha
Axsome Therapeutics (NASDAQ:AXSM) Shares Down 5.6%Here's Why - MarketBeat
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline - ADVFN Brasil
Why Axsome Therapeutics Inc. stock is on top investor watchlistsSuperior stock selection - jammulinksnews.com
What analysts say about Axsome Therapeutics Inc. stockOutstanding capital growth - Autocar Professional
Axsome Therapeutics Inc. Stock Analysis and ForecastRapid growth trajectories - PrintWeekIndia
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stake Raised by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. - MarketBeat
RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM) - The Globe and Mail
New York State Common Retirement Fund Has $3.92 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Is Axsome Therapeutics Inc. stock overhyped or has real potentialUnstoppable trading performance - jammulinksnews.com
How high can Axsome Therapeutics Inc. stock price go in 2025Breakthrough investment results - jammulinksnews.com
How To Trade (AXSM) - news.stocktradersdaily.com
Y Intercept Hong Kong Ltd Invests $1.49 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Is This Stock a Buy After Soaring by 20% in 1 Day? - AOL.com
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now - MSN
Legato Capital Management LLC Buys New Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Is Axsome Therapeutics Inc. a good long term investmentGame-changing returns - Autocar Professional
Leerink Partners Keeps Bullish Stance on Axsome Therapeutics with Buy Rating - AInvest
Lindbrook Capital LLC Cuts Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Optimistic Outlook for Axsome Therapeutics: Promising Pipeline and Potential Sales Growth Drive Buy Rating - TipRanks
Axsome Therapeutics Breaks Below 200-Day Moving AverageNotable for AXSM - Nasdaq
What drives Axsome Therapeutics Inc. stock priceUnprecedented profit potential - jammulinksnews.com
Readystate Asset Management LP Invests $6.95 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - The Globe and Mail
Axsome Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Mizuho reiterates Outperform rating on Axsome Therapeutics stock By Investing.com - Investing.com South Africa
Axsome Therapeutics: Promising Growth Driven by Robust Pipeline and Strategic Fit - TipRanks
Axsome Therapeutics Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Axsome Therapeutics Rings the Opening Bell - Nasdaq
Axsome Therapeutics hosts frontiers in Brain Health R&D Day - TipRanks
Axsome Therapeutics: A CNS Pipeline with High-Impact Catalysts for Long-Term Growth - AInvest
Axsome Therapeutics Hosts R&D Day to Present Comprehensive Data on CNS Pipeline Targeting Alzheimer’s Disease, Depression, Narcolepsy, Fibromyalgia, ADHD, and Smoking Cessation - Nasdaq
Axsome Reveals New Phase 3 Data for 6 Major Brain Disorders: Expert Panel Discusses Breakthrough Treatments - Stock Titan
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today - Lelezard
Axsome Celebrates New CNS Drug Launch with NASDAQ Bell Ringing, Unveils Brain Health Pipeline - Stock Titan
Finanzdaten der Axsome Therapeutics Inc-Aktie (AXSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):